The US Food and Drug Administration (FDA) has cleared Codman & Shurtleff's pre market approval (PMA) application of Medstream Programmable Infusion system, designed as a treatment for spasticity caused by stroke, cerebral palsy, multiple ...
Tags: FDA, Medstream Programmable Infusion system, Medstream system